Selexipag and Hypersensitivity - a phase IV clinical study of FDA data

Summary:

Hypersensitivity is reported as a side effect among people who take Selexipag (selexipag), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Letairis, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Hypersensitivity when taking Selexipag. It is created by eHealthMe based on reports of 2,593 people who have side effects when taking Selexipag from the FDA, and is updated regularly.

What is Selexipag?

Selexipag has active ingredients of selexipag. eHealthMe is studying from 2,593 Selexipag users. Check the latest studies of Selexipag.

What is Hypersensitivity?

Hypersensitivity is found to be associated with 2,748 drugs and 2,917 conditions by eHealthMe. Check the latest studies of Hypersensitivity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

2,593 people reported to have side effects when taking Selexipag.
Among them, 18 people (0.69%) have Hypersensitivity.

Among these 18 people:

How long have people been on Selexipag when they have Hypersensitivity? *

What is the gender of people who have Hypersensitivity when taking Selexipag? *

female: 88.89 %
male: 11.11 %

What is the age of people who have Hypersensitivity when taking Selexipag? *

What are other drugs people take besides Selexipag? *

What are other side effects people have besides Hypersensitivity? *

Nausea (feeling of having an urge to vomit): 6 people, 33.33%
Diarrhea: 5 people, 27.78%
Headache (pain in head): 4 people, 22.22%
Pain: 4 people, 22.22%
Weight Decreased: 3 people, 16.67%
Skin Blushing/flushing (a sudden reddening of the face, neck): 3 people, 16.67%
Dyspnea (difficult or laboured breathing): 3 people, 16.67%
Fatigue (feeling of tiredness): 3 people, 16.67%
Fluid Retention (an abnormal accumulation of fluid in the blood): 3 people, 16.67%
Insomnia (sleeplessness): 3 people, 16.67%

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 9 people, 50.00%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 9 people, 50.00%
Pericardial Effusion (fluid around the heart): 1 person, 5.56%
High Blood Cholesterol: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Selexipag and have Hypersensitivity?

- Check whether Hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Selexipag:

Selexipag (2,593 reports)

Hypersensitivity treatments and more:

Hypersensitivity (272,618 reports)

Browse all side effects of Selexipag:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypersensitivity:

Hypersensitivity (2,748 drugs)

Browse all the conditions that are associated with Hypersensitivity:

Hypersensitivity (2,917 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on selexipag (the active ingredients of Selexipag) and Selexipag (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.